Dirk Sibbing Shares Phase 3 Study on Dissaggpro for STEMI – Rapid Onset and Fast Offset of Antiplatelet Action!
Dirk Sibbing, Professor, Cardiologist and Angiologist at Lauterbacher Mill Private Clinic and LMU Munich, shared on LinkedIn:
”A new drug on the horizon for pre-hospital treatment of STEMI patients
Subcutaneous GPIIb/IIIa – Dissaggpro
Rapid onset and fast offset of antiplatelet action
Phase 3 Study (CeleBrate) of Novel Anti-Platelet Drug for Heart Attack Reports Positive Topline Results as announced by CeleCor Therapeutics
This, for sure, will bring new aspects into the discussions on pretreatment (antiplatelet) for STEMI patients…
Still we are loosing too many patients pre-hospital and before we see them in the cath lab…
Results will be presented as LBCT at AHA 2025 in New Orleans
Arnoud van ‘t Hof, Robert S. Hillman, Jur ten Berg, C. Michael Gibson, M.S., M.D.”
Read the full article here.
Article: Phase 3 Study of Novel Anti-Platelet Drug for Heart Attack Reports Positive Topline Results
Stay updated on all scientific advances in the field with Hemostasis Today.
-
Feb 17, 2026, 16:34ISTH Names Five Global Recipients of 2026 Esteemed Career Awards
-
Feb 17, 2026, 16:16Flora Peyvandi: A Multicenter Initiative to Improve Guideline Adherence in Pediatric ITP
-
Feb 17, 2026, 16:14Hendrianus The: Intravenous Cangrelor in Hemodynamically Unstable Patients Undergoing PCI
-
Feb 17, 2026, 15:42Paul Wischmeyer: Nutrient Absorption in the GI Tract
-
Feb 17, 2026, 15:40Mahesan Subramaniam: Reversing Age-Related Decline in Blood Stem Cells
-
Feb 17, 2026, 15:38Wolfgang Miesbach: How a Single Mutation Can Flip Immunity into VITT
-
Feb 17, 2026, 15:34Jeff June: When Safety Warnings Outlive the Evidence – What Statins Teach Us About Stroke Prevention and Biology
-
Feb 17, 2026, 15:32Gabrielle Sarlon: Key Messages to Improve VTE Management in Women of Childbearing Age
-
Feb 17, 2026, 15:27Piezo1 Gain-of-Function Mutation Explains Thromboembolic Complications in Hereditary Xerocytosis – JTH